Skip to content

Study · Not a test of the peptide alone · 1999

1 result

[Effect of immunomodulators of varying nature on the expression of lymphocyte markers in melanoma patients].

Zaporozhets TS, Likhobabin VIa, Besednova NN, Ermolenko MV, Kiseleva SM

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]1 Jan 1999

PMID10483490 (opens in a new tab)PepBankPUB-10483490
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01LabNot a test of Thymalin aloneIn vitro (cells)Activity measurement

    In melanoma lymphocytes, sensitivity to immunomodulators including thymalin varied by individual, initial marker expression, and drug properties.

    In plain wordsIn lab tests, melanoma lymphocyte sensitivity to immunomodulators including thymalin varied with individual source, initial marker levels, and drug properties.

    Peptide
    Thymalin
    Outcome
    MixedLymphocyte receptor sensitivity
    Study

    humann: not reported in source

    lymphocytes from melanoma patients
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    It was shown in vitro that sensitivity of the lymphocyte receptors of melanoma patients to the immunomodulators was individual and depended on the initial level of the marker expression and the drug properties.
    1 context sentence
    Summary · context
    The influence of immunomodulators such as tactivin, thymalin, gangliin and translam on expression of lymphocyte markers in patients with melanoma was studied.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.